Skip to content

Topical diclofenac versus oral diclofenac in the treatment of mastalgia

Topical diclofenac versus oral diclofenac in the treatment of mastalgia

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-TRC-11001266
Enrollment
Unknown
Registered
2011-04-08
Start date
2011-04-20
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Mastalgia

Interventions

A:oral diclofenac sodium, 50 mg, thrice daily for 7 days
B:topical diclofenac thrice daily for 7 days

Sponsors

Railway hospital
Lead Sponsor

Eligibility

Sex/Gender
Male
Age
13 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Females of age above 12 years; 2. A history of cyclical or non-cyclical mastalgia.

Exclusion criteria

Exclusion criteria: 1. Any associated benign or malignant breast disease; 2. Surgical scar pain; 3. Known allergy to either oral or topical diclofenac; 4. Any side effects noted during the study of both oral or topical diclofenac; 5. Known cases of asthma, peptic ulcer disease, renal or hepatic failure or skin allergies contraindicating the use of the drugs under investigation.

Design outcomes

Primary

MeasureTime frame
cardiff breast pain score;

Secondary

MeasureTime frame
frequency of treatment required after 7 days;side effects of the drug;

Countries

Pakistan

Contacts

Public ContactAfsheen Zafar
zafar_afsheen@yahoo.com+92 0321 5109757

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026